Chest, Vol 98, 1081-1084, Copyright © 1990 by American College of Chest Physicians

ARTICLES

Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis

DM Orenstein, EN Pattishall, PA Nixon, EA Ross and RM Kaplan
Children's Hospital of Pittsburgh 15213.

General quality of life has only recently been measured with an objective tool in patients with cystic fibrosis (CF), and there have been no reported attempts to document changes in patients' overall well- being over time, as patients deteriorate or respond to intervention. We applied the Quality of Well-Being scale (QWB) in 28 patients with CF before and after a two-week course of oral ciprofloxacin used to treat pulmonary exacerbations. There were significant correlations between changes in QWB and various pulmonary function test results; QWB vs FEV1: r = 0.4, p less than 0.03; QWB vs FVC: r = 0.5, p less than 0.01; and QWB vs SaO2: r = 0.4, p less than 0.05. Thus, the QWB can track changes in general well-being in CF patients over a brief time and detect changes associated with pulmonary exacerbation and its treatment.

This article has been cited by other articles:

				R. L. Gibson, J. L. Burns, and B. W. Ramsey Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951. [Abstract] [Full Text] [PDF]

				National Emphysema Treatment Trial Research Group Cost Effectiveness of Lung-Volume-Reduction Surgery for Patients with Severe Emphysema N. Engl. J. Med., May 22, 2003; 348(21): 2092 - 2102. [Abstract] [Full Text] [PDF]

				L. G Wood, D. A Fitzgerald, A. K Lee, and M. L Garg Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function Am. J. Clinical Nutrition, January 1, 2003; 77(1): 150 - 159. [Abstract] [Full Text] [PDF]

				L. G Wood, D. A Fitzgerald, P. G Gibson, D. M Cooper, and M. L Garg Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients Am. J. Clinical Nutrition, April 1, 2002; 75(4): 668 - 675. [Abstract] [Full Text] [PDF]

				M. T. Britto, U. R. Kotagal, R. W. Hornung, H. D. Atherton, J. Tsevat, and R. W. Wilmott Impact of Recent Pulmonary Exacerbations on Quality of Life in Patients With Cystic Fibrosis Chest, January 1, 2002; 121(1): 64 - 72. [Abstract] [Full Text] [PDF]

				A. L. Quittner, S. Sweeny, M. Watrous, P. Munzenberger, K. Bearss, A. G. Nitza, L. A. Fisher, and B. Henry Translation and Linguistic Validation of a Disease-Specific Quality of Life Measure for Cystic Fibrosis J. Pediatr. Psychol., September 1, 2000; 25(6): 403 - 414. [Abstract] [Full Text] [PDF]

				D J FRENCH Quality of life in cystic fibrosis Thorax, September 1, 1998; 53(9): 721 - 722. [Full Text]

				B. W. Ramsey Management of Pulmonary Disease in Patients with Cystic Fibrosis N. Engl. J. Med., July 18, 1996; 335(3): 179 - 188. [Full Text] [PDF]